These findings provide mechanistic insight into how mitochondrial antioxidants shape the cardiomyocyte response to ischemic injury and suggest that enhancing PrxIII function may represent a novel therapeutic approach in I/R-related cardiac disease. This evidence concerns the gene PRDX3 and heart disorder.